Adverse Events According to Common Toxicity Criteria for Adverse Events, Version 4.0
| Baseline | After radioligand therapy | |||||||
| Event | Grade 0 | Grade 1 | Grade 2 | Grade 3 | Grade 0 | Grade 1 | Grade 2 | Grade 3 |
| WBCs | 74 (90.2%) | 6 (7.3%) | 2 (2.4%) | 0 (0%) | 62 (84%) | 8 (10.8%) | 4 (5.4%) | 0 (0%) |
| Hemoglobin | 26 (31.7%) | 40 (48.8%) | 11 (13.4%) | 5 (6.1%) | 47 (63.5%) | 16 (21.6%) | 10 (13.5%) | 1 (1.4%) |
| Platelets | 67 (81.7%) | 11 (13.4%) | 3 (3.7%) | 1 (1.2%) | 57 (77%) | 15 (20.2%) | 1 (1.4%) | 1 (1.4%) |
| Creatinine | 81 (98.8%) | 1 (1.2%) | 0 (0%) | 0 (0%) | 70 (94.5%) | 4 (5.5%) | 0 (0%) | 0 (0%) |
| Nausea | 74 (90.2%) | 8 (9.8%) | 0 (0%) | 0 (0%) | 73 (98.6%) | 1 (1.4%) | 0 (0%) | 0 (0%) |
| Diarrhea | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Xerostomia | 78 (95.1%) | 3 (3.6%) | 1 (1.2%) | 0 (0%) | 67 (90.6%) | 7 (9.4%) | 0 (0%) | 0 (0%) |
WBCs = white blood cells.
There was no treatment-associated grade 4 or 5 toxicity.